In Brief | Oncology & Hepatology
ONCOLOGY: One in Five Patients with Unresectable HCC Alive at 5 Years on STRIDE Regimen
[13 July 2026]
Study Snapshot
| Design | Phase III HIMALAYA trial (NCT03298451) — updated exploratory analysis of overall survival (OS) at 5 years of follow-up; data cut-off 1 March 2024 |
| Population | Patients with unresectable hepatocellular carcinoma (HCC); STRIDE arm n=393, sorafenib arm n=389 |
| Comparison | STRIDE (single priming dose tremelimumab + regular-interval durvalumab) vs. sorafenib |
| Primary Outcome | 60-month OS: 19.6% (STRIDE) vs. 9.4% (sorafenib); OS HR 0.76 (95% CI 0.65–0.89) |
Summary
Unresectable HCC has historically carried a poor long-term prognosis. This updated exploratory analysis of the phase III HIMALAYA trial reports the first 5-year OS data for a phase III regimen in this setting.
Participants were randomised to STRIDE, durvalumab monotherapy, or sorafenib; OS, depth of tumour response and serious adverse events (SAEs) were assessed, with extended long-term survivors defined as those alive ≥48 months post-randomisation. Median follow-up was 62.49 months (STRIDE) and 59.86 months (sorafenib).
At 60 months, OS with STRIDE was 19.6% versus 9.4% with sorafenib overall, rising to 28.7% versus 12.7% in patients achieving disease control and 50.7% versus 26.3% in those with over 25% tumour shrinkage. Extended long-term survivors were more common with STRIDE (83/393, 21.1%) than sorafenib (45/389, 11.6%), across all clinically relevant subgroups, and no late-onset treatment-related SAEs were reported with STRIDE.
The findings reinforce STRIDE's durable survival benefit and suggest response depth—not just disease control—may better predict who benefits most.
References
Disclaimer
